Bristol-Myers Squibb (NYSE: BMY ) is expected to report Q4 earnings on Jan. 24. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Bristol-Myers Squibb's revenues will shrink -24.0% and EPS will contract -18.9%.
The average estimate for revenue is $4.15 billion. On the bottom line, the average EPS estimate is $0.43.
Last quarter, Bristol-Myers Squibb logged revenue of $3.74 billion. GAAP reported sales were 30% lower than the prior-year quarter's $5.35 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.41. GAAP EPS were -$0.43 for Q3 against $0.56 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 75.0%, 100 basis points better than the prior-year quarter. Operating margin was 20.4%, 1,390 basis points worse than the prior-year quarter. Net margin was -19.0%, 3,710 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $17.57 billion. The average EPS estimate is $1.96.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,708 members out of 1,820 rating the stock outperform, and 112 members rating it underperform. Among 504 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 486 give Bristol-Myers Squibb a green thumbs-up, and 18 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bristol-Myers Squibb is hold, with an average price target of $34.88.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Bristol-Myers Squibb. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Bristol-Myers Squibb to My Watchlist.